Posted by Michael Wonder on 29 Nov 2022
Roche withdraws Tecentriq from US bladder cancer indication
29 November 2022 - Roche has voluntarily withdrawn the US indication of Tecentriq for treating a form of bladder cancer following consultation with the FDA, the Swiss drugmaker said on its website on Tuesday.
The move follows the failure of a clinical trial that aimed to convert accelerated approval of the drug to regular approval for this indication, Roche said. The decision does not affect other approved indications for Tecentriq in the U.S. market.
